Gilead Sciences said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling ...
Gilead Sciences said on Monday its experimental HIV treatment met the main goal and was found to be statistically ...
Investigational Treatment Regimen Could Expand Options for Virologically Suppressed Adults –– Positive Phase 3 Results from ...
Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.
Gilead's ARTISTRY-2 trial shows BIC/LEN is non-inferior to Biktarvy in virologically suppressed adults with HIV, with no new safety signals. ARTISTRY-2's design involved a randomized, double-blind ...
Gilead Sciences said its in-development HIV treatment met the primary endpoint of a recent late-stage clinical trial. The biopharmaceutical company said Monday that the treatment, a once-daily single ...
By Dana PiccoliNEWS IS OUT The Choose U World AIDS Day panel brought together three longtime advocates living with HIV to ...
Choose San Francisco Business Times as a preferred news source to see more of our reporting on Google. It is the first work ...
By shutting South Africa out of its overseas funding for the roll-out of the revolutionary six-monthly HIV prevention jab ...
Over time, clonal expansion leads to an increase in the frequency of infected cells in a patient. The proviruses in daughter ...
Paper in @jclinicalinvest (bit.ly/497z6jo) by @HopkinsMedicine @JHUMed_ID finds patient living w/ #HIV has dramatic drop in ...
Advancements in HIV/AIDS research, drug development and clinical practice since the 1980s have made it possible for people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback